Medical Devices & Equipment Company

Aegis Medical Innovations

3%

Funding Goal $3,500,000
Funding Raised So Far $0
Funding Commitments $100,000
Funding Remaining $3,400,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

Aegis has developed a surgically implanted device that reduces the risk of stroke in patients suffering from irregular heartbeat by preventing the flow of blood between the heart and left atrial appendage on the left side of the heart.

The surgically implanted device, called Sierra, has been in development for 11+ years with over $15 million invested. The FDA empanelled a group of experts, who after detailed study advised they did not find a single opportunity for improvement. Aegis wishes to undertake a 50-60 patient trial - take 12-18 months, cost $3.5mm, with objective to earn a CE Mark approval for commercial sale of Sierra in Europe.

There is a natural pool of buyers for Aegis/Sierra on grant of CE Mark. The precedent transaction is Boston Scientific's purchase of Atritech and its Watchman device, for an up front payment of $100mm and milestone payments of $275mm, 12+ years ago. Their 2022 revenue from their Watchman franchise has eclipsed $1 Billion.. Abbott Laboratories acquired their Amulet device as part of their St. Jude Medical purchase in 2017, with FDA approval granted in 2021. Johnson and Johnson acquired their Wavecrest device in 2015 and Atricure Inc. purchased their Lariat device in 2019. All were first CE Mark approved, prior to initial commercial market entry.

Besides being a better, cheaper, faster, safer device, Sierra has two distinct advantages. due to Sierra's epicardial deployment (as opposed to endocardial deployment.) . In about 15% of the patients Sierra, also cures A-Fib and can potentially be a very effective treatment for hypertension. Sierra, atrial fibrillation ("SierraAF") and hypertension ("SierraHT") present the potential opportunity to, at some point, split Aegis into two companies.

Low risk is i) the conclusions reached in the FDA review, ii) same doctor that ran Aegis successful
7 patient trial 3 years ago will run our planned 50-60 person triaI iii) Aegis is navigating familiar waters, iv) Boston Scientific and other majors have proven the efficacy, demand, profitability, market, and the procedure is now health insurance supported in many cases.

Investor Q&A calls: Twice daily (10am & 4pm PST) Monday-Friday/Robert > Call 1-727-731-5165

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Investor Sign Up
Investor Log In

Business Summary

Company Age 12 years
Employees 5
Sub-Industry Surgical
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services

Sierra Ligation System

Development based on IP Licensed from 3 Cardiologists at Mayo Clinic. Worked in close partnership with a leading American academic medical clinic and Biomerics LLC partners to develop a (patent protected) engineered device that can deliver a simpler, cheaper and safer percutaneous epicardial procedure for left atrial appendage (LAA) closure.
The “Sierra” is one of the only “single access” epicardial (LAA) closure devices and procedures known to be in development;

• Patented electrocardiogram (ECG) navigation for less invasive and more accurate closure
• Patented hollow structure ligation
• One size fits all economics
• Repositionable design
• Elimination of Heparin or post procedure oral anticoagulation (OAC)

Features: 1. Single access, no need to enter circulation or manage two access points. 2. Shortest implant times 3. Safety, no device left in LAA 4. Efficacy: Reduce stroke, hypertension & potential - reductions in BP. Better closure rates of LAA to prevent clots.

Management

Robert Pirooz
Director Chairman
Robert P......

EXECUTIVE CHAIR, Bcomm., J.D., Q.C.
• Venture Capitalist, Lawyer
• Performed a variety of instrumental roles in the formation,
development and/or operation of over 11 public companies, 8 of these were sold for
proceeds in excess of $1.6 billion. The largest of those remaining, Pan American Silver Corp,
has a market Capitalization of $12 billion
• Juris Doctorate from the University of British Columbia
• Graduate degree in commerce from Dalhousie University
• Appointed Queen's Counsel, in 2012

Dr. Krzysztof Bartus
Consulting Physician/Medical Officer
Dr. K......

World's Top Physician, M.D., Ph.D.
• Professor of Medicine - Jagiellonian University, Department of Cardiovascular and
Transplant Surgery. Ph.D. in medical sciences
• Surgeon – Cardiothoracic, specializing in Surgical and hybrid management of subjects with
atrial fibrillation and has regularly been engaged for clinical trials
• Depth of experience in developement of new techniques and devices for interventional
cardiology and cardiac surgery
• Performed first Aegis trial and will perform subsequent trials
• Investigator, Co-Investigator and Clinical study coordinator in more than 100 Clinical Trials. Most FDA controlled
• Primary investigator and Co investigator in 30 first in man clinical studies (as of 2022)
• Author and co-author of 177 publications including publications in Lancet, European Journal
of Cardio-Thoracic Surgery, Annals of Thoracic Surgery, Acta Cardiologica, Cell Tissue
Banking, Heart Surgery Forum, America

Martin Rip
Chief Financial Officer
Martin R......

CHIEF FINANCIAL OFFICER, CPA, CA, ACA., LLB Hons
• Chartered Professional Accountant (CPA, CA) with over 25 years experience including public
practice
• Member of the Chartered Professional Accountants of British Columbia and The Institute of
Chartered Accountants in England and Wales
• Extensive experience in financial reporting and internal controls compliance for public
companies
• Extensive experience leading and coordinating corporate acquisitions and dispositions
• CPA, CA Designation (Canada)
• Chartered Accountant (ACA) Qualification in UK
• Law with French (LLB Hons), University of Birmingham

Vice President Advisor
Amber S......

VICE PRESIDENT, REGULATORY COMPLIANCE AND CORPORATE SECRETARY
• More than 25 years of public company experience including corporate affairs, legal and regulatory administration, securities compliance, and governance.
• Paralegal Diploma from Capilano University

Alexis Stewart
General Counsel/Legal Officer
Alexis S......

GENERAL COUNSEL, LLB
• Experienced corporate lawyer and entrepreneur with a demonstrated history of providing legal services in the high tech, insurance, mining and entertainment industries.
•Skilled in advising early-stage businesses on matters ranging from going-public transactions, licensing and asset purchases, regulatory and securities compliance, to investor relations and internal management and employment issues.
•Law and undergraduate degrees from University of British Columbia.

Investors/Lenders

Individual Investor
Robert Pirooz

EXECUTIVE CHAIR, Ageis Medical Innovation, Bcomm., J.D., Q.C.
• Venture Capitalist, Lawyer
• Performed a variety of instrumental roles in the formation,
development and/or operation of over 11 public companies, 8 of these were sold for
proceeds in excess of $1.6 billion. The largest of those remaining, Pan American Silver Corp,
has a market Capitalization of $12 billion
• Juris Doctorate from the University of British Columbia
• Graduate degree in commerce from Dalhousie University
• Appointed Queen's Counsel, in 2012

Amount
Investment Type
Investment Round
Investment Date

3%

Funding Goal $3,500,000
Funding Raised So Far $0
Funding Commitments $100,000
Funding Remaining $3,400,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents

Contact

Aegis Medical Innovations

Vancouver, BC V7M 2J5, Canada

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).